Detecting Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma
V600 BRAF mutation was identified as an ideal target for clinical therapy due to its indispensable roles in supporting melanoma initiation and progression. Despite the fact that BRAF inhibitors (BRAFi) can elicit anti-tumor responses in the majority of treated patients and confer overall survival benefits, acquired drug resistance is a formidable obstacle to long-term management of the disease. Several aberrant events including RTK upregulation, NRAS mutation, mutant BRAF amplification or alternative splicing, and MEK mutation have been reported as acquired BRAFi resistance mechanisms. Clinially, detection of these resistance mechanisms help understand drug response patterns and help guide combinatorial therapeutic strategies. Therefore, quick and accurate diagnosis of the resistant mechanisms in tumor biopsies has become an important starting point for personalized therapy. In this chapter, we review the major acquired BRAFi resistance mechanisms, highlight their therapeutic implications, and provide the diagnostic methods from clinical samples.
- Regulation of NF-B by Oncoproteins and Tumor Suppressor Proteins
- Activation of Caspase Protease During Apoptosis in Ovarian Cancer Cells
- Identification of Malignant Plasma Cells by mRNA In Situ Hybridization
- Detection of Chromosomal Deletions by Microsatellite Analysis
- Clinical Application of Tissue and Serum Markers in Breast Cancer
- Detection of Aberrant Glycosylation in Breast Cancer Using Lectin Histochemistry
- Bisulfite Methylation Analysis of Tumor Suppressor Genes in Prostate Cancer from Fresh and Archival Tissue Samples
- Flow Cytometry Enumeration of Apoptotic Cancer Cells by Apoptotic Rate
- 小鼠椎体感光器单细胞吸入记录
- GFP转染后克隆筛选